Table 2. Characteristics of the patients in the primary cohort and validation cohort.
| Characteristics | Primary cohort |
P | Validation cohort |
P | ||
|---|---|---|---|---|---|---|
| Benign | Malignant | Benign | Malignant | |||
| Age (yr, mean ± SD) | 49.60 ± 12.94 | 62.78 ± 11.59 | <0.001* | 50.43 ± 14.55 | 59.77 ± 11.42 | <0.001* |
| Gender | ||||||
| Male | 17 (56.7%) | 54 (60%) | 0.745 | 17 (56.7%) | 49 (54.4%) | 0.832 |
| Female | 13 (43.3%) | 36 (40%) | 13 (43.3%) | 41 (45.6%) | ||
| Score (Median[IQR]) | ||||||
| Group 1 | −0.091 (−1.170, 1.052) | 2.004 (1.155, 2.448) | <0.001* | 0.250 (−0.713, 1.449) | 1.776 (0.938, 2.248) | <0.001* |
| Group 2 | 0.374 (−1.031, 1.273) | 1.870 (1.218, 2.341) | <0.001* | 0.508 (−0.717, 1.526) | 1.606 (0.916, 2.339) | <0.001* |
| Group 3 | 0.393 (−0.254, 1.307) | 1.548 (1.177, 2.180) | <0.001* | 0.458 (−0.607, 1.634) | 1.620 (1.096, 1.966) | <0.001* |
| Group 4 | 0.636 (−0.190, 1.390) | 1.474 (1.046, 1.897) | <0.001* | 0.622 (−0.064, 1.603) | 1.358 (1.102, 1.746) | <0.001* |
Note: IQR = inter-quartile range; Group 1 = non-contrast + 1.25 mm + standard convolution kernel; Group 2 = contrast enhancement + 1.25 mm + standard convolution kernel; Group 3 = non-contrast + 5 mm + standard convolution kernel; Group 4 = non-contrast + 5 mm + lung convolution kernel. p-value is derived from the univariable association analyses between each of the clinicopahological variables and the SPN status. “*” indicates a p-value less than 0.05.